FOXK2 antibody - C-terminal region (P100774_T100)
- Known as:
- FOXK2 (anti-) - C-terminal region (P100774_T100)
- Catalog number:
- p100774_t100
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- FOXK2 antibody - C-terminal region (P100774_T100)
Related genes to: FOXK2 antibody - C-terminal region (P100774_T100)
- Gene:
- FOXK2 NIH gene
- Name:
- forkhead box K2
- Previous symbol:
- ILF, ILF1
- Synonyms:
- -
- Chromosome:
- 17q25.3
- Locus Type:
- gene with protein product
- Date approved:
- 1992-02-13
- Date modifiied:
- 2016-10-05
Related products to: FOXK2 antibody - C-terminal region (P100774_T100)
Related articles to: FOXK2 antibody - C-terminal region (P100774_T100)
- MYST lysine acetyltransferases (KATs) are a class of epigenetic enzymes critical for cellular function that constitute an emerging therapeutic target in cancer. Recently, several drug-like MYST inhibitors have been reported that show promise in preclinical models as well as in clinical trials of breast cancer. Understanding the specificity of these molecules is critical for their effective use as chemical probes. Here we apply an integrated profiling strategy to systematically define the potency and selectivity of drug-like MYST KAT inhibitors. First, we use optimized chemoproteomic profiling and histone acetylation biormarkers to study the industry-developed KAT inhibitor PF-9363. This reveals dose-dependent engagement of native KAT complexes, with hierarchical inhibition following the order KAT6A/B > KAT7 » KAT8 > KAT5. This pattern of target engagement is shared by the clinical candidate PF-8144. Next, we demonstrate how PF-9363's ability to disrupt capture of MYST complex members in chemoproteomic experiments can be leveraged to identify uncharacterized candidate members of these complexes, including the transcription factor FOXK2. Applying insights from these studies to WM-8014, WM-1119 and WM-3835, which have been extensively applied in the literature as MYST probes, highlights unexpected cross-inhibition and suggests a framework for how these small molecules and biomarkers may be applied to differentiate KAT6A/B and KAT7-dependent phenotypes. Finally, we benchmark the activity of PF-9363 in the NCI-60 cell line screen, providing evidence that its ability to engage KAT8 at elevated concentrations can drive acute growth inhibition. Collectively, our studies indicate the potential for MYST KAT inhibitors, including clinical candidates, to exhibit dose-dependent target engagement reminiscent of kinase inhibitors. The assays and biomarkers described here should find broad utility in assessing selective target engagement by this inhibitor class. - Source: PubMed
Publication date: 2026/05/13
Chen XueminCastroverde AlexandraPerez MinervoHolewinski RonaldSuazo Kiall FKarki RashmiAndresson ThorkellGarcia Benjamin AMeier Jordan L - Papillary thyroid carcinoma (PTC) is the most prevalent malignant tumor of the endocrine system, yet the specific role of Forkhead box protein K2 (FOXK2) in its progression remains incompletely elucidated. Analyses based on public databases and 31 pairs of matched clinical specimens revealed that both FOXK2 and SH2D3A were significantly upregulated in PTC tissues and cell lines, with their expression levels showing a strong positive correlation. Functional experiments indicated that knockdown of FOXK2 or SH2D3A markedly inhibited PTC cell proliferation, invasion, and migration while reducing the phosphorylation of p38, ERK, and AKT. In FOXK2-knockdown cells, SH2D3A overexpression partially restored these oncogenic phenotypes and the activation of downstream signaling, a result further validated in nude mouse xenograft models. Mechanistically, FOXK2 was found to enhance SH2D3A transcription by directly binding to its promoter region. Co-immunoprecipitation assays further confirmed that SH2D3A directly interacts with the epidermal growth factor receptor (EGFR). Importantly, pharmacological inhibition of EGFR with Gefitinib effectively suppressed the activation of EGFR and ERK, thereby attenuating the oncogenic activity of the FOXK2/SH2D3A axis. Collectively, this study identifies a novel FOXK2/SH2D3A/EGFR signaling axis that contributes to PTC progression and may represent a potential therapeutic vulnerability in aggressive papillary thyroid cancer. - Source: PubMed
Publication date: 2026/04/15
Cui QinHong XulinGan LinShi Bimin - FOXK2 is a transcription factor known to regulate a wide range of biological processes that are critically involved in determining cell fate. Increasing evidence shows aberrant FOXK2 expression in some tumors, with crucial biological and clinical impacts. It is important to note that the molecular mechanisms contributing to gene deregulation are poorly understood for most cancers. In this review, we systematically describe the gene expression profile across distinct tumor types and discuss its potential utility as a prognostic and diagnostic molecular marker. Notably, we explore emerging mechanisms accounting for deregulation, focusing on genetic and transcriptional modifications, such as gene methylation, mutation and copy number variations. - Source: PubMed
Publication date: 2025/11/24
Vasconcelos Renata IvoCarneiro Luciana da TorreMaia Raquel CiuvalschiHancio ThaísNestal de Moraes Gabriela - Pacific oysters (Crassostrea gigas) are a major aquaculture species among molluscs worldwide, possessing significant ecological and economic value. The mechanism governing sex determination in oysters remains largely unknown. Fox transcription factors are key regulators of vital biological processes, controlling important functions such as tissue development and reproduction. This study presents a genome-wide identification and characterization of the Fox gene family in C. gigas. Through systematic identification, 16 Fox genes were discovered and classified into 13 subfamilies based on phylogenetic analysis and conservation domain analysis. Transcriptomic profiling revealed that FoxK2 and FoxG1 were significantly upregulated during the resting stage, whereas FoxG1 expression was higher in females and males throughout the active gametogenesis stage (P < 0.05). FoxE1 and FoxL2 exhibited elevated expression profiles during female maturation, whereas FoxO, FoxN4, and FoxK2 showed higher expression profiles during male maturation (P < 0.05). At the spawning stage, FoxE1 and FoxK2 were significantly expressed in females, whereas FoxJ1B and FoxK2 exhibited elevated expression in males (P < 0.05). Our findings indicate sexually dimorphic expression patterns of FoxB1, FoxE1, FoxL2, FoxP1, and FoxC1 and their gonad-specific functions. Our research has significant ecological implications for comprehending the sex determination process and offers fresh insights into the Fox gene regulation mechanisms in bivalves. - Source: PubMed
Publication date: 2026/03/22
Chen SitongLi QiHu BiyangDu Shaojun - Cancer is the second leading cause of death in both developed and developing countries. In cancer cells, hemostasis is disrupted, a process that is maintained under normal conditions in healthy cells. Transcription factors that play a crucial role in preserving this hemostasis have been linked to cancer. In recent years, the involvement of proteins from the FOX transcription factor family in cancer development has been extensively studied, highlighting their potential relevance for therapeutic research. Although one of these proteins, Forkhead Box K2 (FOXK2), was identified in the early 1990s, its biological functions in cellular processes remain incompletely understood. Research has highlighted the roles of FOXK2 in critical molecular processes, including de novo nucleotide synthesis, the expression of metabolic-related enzymes, DNA mismatch repair, cell proliferation, differentiation, apoptosis, and autophagy. Furthermore, it has been shown that FOXK2 mediates the binding of transcription factors that do not directly interact with methylated DNA to methylated regions, and also influences the DNA methylation process. Studies investigating its role in cancer indicate that FOXK2 functions as an oncogenic in certain tissues while acting as a tumor suppressor in others. The role of FOXK2 is particularly controversial, especially in hormone-dependent diseases. In this review, the roles of FOXK2 in various cancer cell types were analysed. Additionally, Gene Ontology (GO) enrichment analyses of miRNAs targeting FOXK2 were conducted, highlighting aspects of FOXK2 that have yet to be explored. GO analysis revealed that miRNAs targeting FOXK2 are particularly involved in regulatory processes. In conclusion, FOXK2 may represent a potential therapeutic target in certain cancer types, although its context-dependent roles require further investigation. - Source: PubMed
Publication date: 2026/02/03
Akin SeydaOzturk İbrahimHepokur Ceylan